Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MPL | P40238 | 2/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | ASPH | Q12797 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL31491067 | 0.90 | PIK3CA (0.33) | PIK3CAMAP3K12ASPH | |
| SCHEMBL31214202 | 0.83 | HPGD (0.36) | HPGDHSD17B10AURKAKDRAURKB | |
| SCHEMBL13973112 | 0.83 | HPGD (0.36) | HPGDHSD17B10AURKAKDRAURKB | |
| SCHEMBL29435785 | 0.82 | MBOAT4 (0.36) | HPGDHSD17B10AURKAKDRAURKB | |
| SCHEMBL9276814 | 0.82 | MBOAT4 (0.36) | HPGDHSD17B10AURKAKDRAURKB | |
| Ammonia Solution, Strong SCHEMBL16280437 | 0.80 | MBOAT4 (0.35) | HPGDHSD17B10AURKAKDRAURKB | |
| SCHEMBL31372473 | 0.79 | ASPH (0.32) | ASPH | |
| SCHEMBL31240982 | 0.78 | LMNA (0.38) | HPGDHSD17B10AURKAKDRAURKB | |
| SCHEMBL21606876 | 0.78 | PIK3CD (0.36) | HPGDHSD17B10AURKAKDRAURKB | |
| SCHEMBL6739221 | 0.78 | ASPH (0.34) | AURKAASPH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049274-A2 | TETRACYCLIC DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| EP-4322954-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2024-02-21 | — | — | EP | disclosed |
| EP-4320132-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022221739-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022216762-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | HPGD 816/4885HSD17B10 4468/4885MPL 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.